Clinical trials: Dementia, completed
Schizophrenia
Staccato Loxapine in Agitation (Proof of Concept)
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients.
- Trial name
- NCT00369577
- Testing
- Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Major Depressive Disorder, Anxiety Disorders
IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)
This study will evaluate a Smartphone intervention for depression and anxiety that uses machine learning to tailor treatment for patients.
- Trial name
- NCT02176226
- Testing
- IntelliCare
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Northwestern University
Stroke, Dementia
Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO)
Background: Recent studies have demonstrated that even mild stroke survivors experience residual damage, which persists and in fact increases in subsequent years.
- Conditions
- Stroke, Dementia, Cerebrovascular Disorders, Alzheimer's Disease
- Trial name
- TABASCO (NCT01926691)
- Where
- Israel
- Volunteers
- 575 people
- Sponsor
- Eli Sprecher, MD
Healthy
Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population
To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.
- Trial name
- NCT00547560
- Testing
- GSI-953
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Dementia, Alzheimer Disease
Volunteers Adding Life in Dementia
The objectives of our project are to: 1.) Develop a training program and manual for volunteers to implement evidence-based, non-pharmacological interventions for neuropsychiatric symptoms (NPS) of dementia in long-term care (LTC)…
- Conditions
- Dementia, Alzheimer Disease, Behavior
- Trial name
- VALID (NCT01646723)
- Testing
- Volunteers Adding Life in Dementia (VALID) Program
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Queen's University
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Early Alzheimers Disease, Mild Cognitive Impairment Due to AD
A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
This is a phase 2B multicenter, randomized, double-blind, placebo-controlled, parallel group dose finding study to evaluate the safety, tolerability and efficacy of PQ912, an inhibitor of the glutaminyl cyclase enzyme, in 250…
- Trial name
- VIVIAD (NCT04498650)
- Testing
- PQ912
- Where
- 21 sites in Denmark, Germany and 3 more
- Volunteers
- 259 people
- Sponsor
- Vivoryon Therapeutics N.V.
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Epilepsy, Alzheimer Disease
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT07222878
- Testing
- NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Parkinson's Disease, Sleep Disordered Breathing
Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease
Patients with sleep disordered breathing (SDB), also called sleep apnea, experience nighttime disrupted sleep and, because they stop breathing for short periods during the night, do not get sufficient oxygen to their brains.
- Trial name
- TAP (NCT00492115)
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- University of California, San Diego
Dementia
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Alzheimer's disease (AD) is increasing exponentially, with a projected quadrupling of cases by the mid 21st century. Individuals with AD are at increased risk for a host of medical and psychiatric conditions, and evidence is…
- Trial name
- NCT01550718
- Testing
- ESML-EX (Physical Activity Program), ESML-Social (Social Activity Program)
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Washington
Alzheimer's Disease, Psychomotor Agitation
Escitalopram Treatment of Patients With Agitated Dementia
The purpose of this study is to determine the safety and efficacy of escitalopram (Lexapro) using 10 or 20 mg daily in patients with Alzheimer's disease who are also experiencing agitation.
- Trial name
- NCT00260624
- Testing
- Escitalopram (Lexapro)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Alzheimer Disease, Parkinson Disease
P-glycoprotein Function in Brain Diseases
This study will measure the function of a protein called P-glycoprotein (P-gp), which is found at the blood-brain barrier, a membrane that normally prevents toxic material from entering the brain.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Lobar Degeneration
- Trial name
- NCT00677885
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer Disease
Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
- Trial name
- NCT00007189
- Testing
- Naproxen Sodium (Aleve), Celecoxib (Celebrex)
- Where
- 6 sites in United States
- Volunteers
- 2,625 people, healthy volunteers welcome
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Child Behavior Problem, Disruptive Behavior
Pilot Study of Parent Training With Role-plays in Virtual Reality for Parents of Children With Behavior Problems
The main aim of this pilot trial is to evaluate preliminary effects and feasibility of a new parent training program for parents of children aged 8-16 years with disruptive behavior (e.g., angry, aggressive or defiant behavior).
- Conditions
- Child Behavior Problem, Disruptive Behavior, Oppositional Defiant Disorder, Conduct Problems
- Trial name
- NCT06559813
- Testing
- Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Karolinska Institutet
Cardiovascular Diseases, Coronary Disease
Honolulu Heart Program
To investigate coronary heart disease and stroke among American men of Japanese ancestry who were living on the island of Oahu in 1965. Morbidity and mortality surveillance of the original cohort is continuing.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Cerebrovascular Accident, Heart Diseases
- Trial name
- NCT00005123
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Dementia Mild, Mild Cognitive Impairment
An Advance Care Planning Programme for Persons With Early Stage Dementia in the Community
Advance care planning (ACP) has been widely advocated for persons with early stage dementia (PWEDs) and persons with mild cognitive impairment (MCI).
- Trial name
- NCT04491578
- Testing
- ACP programme "Have a Say"
- Where
- 10 sites in Hong Kong
- Volunteers
- 100 people
- Sponsor
- Hong Kong Metropolitan University
Mild Cognitive Impairment
Metformin in Amnestic Mild Cognitive Impairment
Hyperinsulinemia and type 2 diabetes (T2D) are important potential risk factors for cognitive decline and Alzheimer's disease (AD).
- Trial name
- MCI (NCT00620191)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Dementia, Alzheimer Disease
Assessing Acceptability, Cost, and Efficacy of STELLA-Support Via Technology
STELLA (Support via Technology Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent video-conference based intervention that aims to help family members caring for persons of dementia…
- Conditions
- Dementia, Alzheimer Disease, Caregiver Burnout, Family Members
- Trial name
- STELLA (NCT04335110)
- Testing
- STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Oregon Health and Science University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.